Transfusion medicine: Support of patients undergoing cardiac surgery

American Journal of Cardiovascular Drugs

Volumn 1, Issue 5, 2001, Pages 337-351

  Goodnough, Lawrence T ^a   Despotis, George J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL TRIAL; HEART SURGERY; HEMODILUTION; HEMOSTASIS; HUMAN; INTENSIVE CARE; METHODOLOGY; PEROPERATIVE CARE; POSTOPERATIVE CARE; REVIEW;

BLOOD LOSS, SURGICAL; BLOOD SPECIMEN COLLECTION; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS; CRITICAL CARE; ERYTHROPOIETIN, RECOMBINANT; HEMODILUTION; HEMOSTASIS, SURGICAL; HUMANS; INTRAOPERATIVE CARE; POSTOPERATIVE CARE;

EID: 2442481588     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101050-00004     Document Type: Review

References (159)

1. Goodnough LT, Brecher ME, Kanter MH, et al. Blood transfusion. N Engl J Med 1999; 340: 439-47
2. Goodnough LT, Brecher ME, Kanter MH, et al. Blood conservation. N Engl J Med 1999; 340: 525-33
3. Spahn DR, Casutt M. Eliminating blood transfusions. Anesthesiology 2000; 93: 242-55
4. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. JAMA 2000; 284: 229-35
5. Finucane ML, Slovic P, Mertz CK. Public perception of the risk of blood transfusion. Transfusion 2000; 40: 1017-22
6. Hebert PC, Wells G, Marshall J, et al: Transfusion requirements in critical care. JAMA 1995; 273: 1439-44
7. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29: 227-34
8. Hebert PC, Wells G, Blajchman MA, et al. Transfusion requirements in critical care. A multicenter randomized controlled clinical trial. N Engl J Med 1999; 340: 409-17
9. Corwin HL, Krantz SB. Anemia of the critically ill: ?acute? anemia of chronic disease. Crit Care Med 2000; 28: 3098-9
10. Van Iperen CE, Gaillard CAJM, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28: 2773-8
11. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebocontrolled trial. Crit Care Med 1999: 27: 246-50
12. Goodnough LT, Johnston MFM, Toy PTCY, et al. The variability of transfusion practice in coronary artery bypass graft surgery. JAMA 1991; 265: 86-90
13. Surgenor DM, Wallace EL, Churchill WH, et al. Red cell transfusions in coronary artery bypass surgery. Transfusion 1992; 32: 458-64
14. Stover EP, Siegel LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines. Anesthiology 1998; 88: 327-33
15. National Institutes of Health Consensus Conference. Perioperative red cell transfusion. JAMA 1988; 260: 2700-5
16. American Society of Anesthesiologists task force. Practice guidelines for blood component therapy. Anesthesiology 1996; 84: 752-47
17. Goodnough LT, Soegiarso RW, Birkmeyer JD, et al. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med 1993; 94: 509-14
18. Surgenor DM, Churchill WH, Wallace EL. The specific hospital influences red cell and component transfusion in coronary artery bypass graft surgery. A study of five hospitals. Transfusion 1998; 37: 122-34
19. Robertie PG and Gravlee GP. Safe limits of isovolemic hemodilution and recommendations for erythrocyte transfusion. Int Anesthesiol Clin 1990; 28: 197-204
20. Faust RJ. Perioperative indications for red blood cell transfusion - has the pendulum swung too far? Mayo Clin Proc 1993; 68: 512-4
21. Goodnough LT, Despotis GJ, Hogue CW, et al. On the need for improved transfusion indicators in cardiac surgery. Ann Thorac Surg 1995; 60: 473-80
22. Bryan-Brown CW, Baek SM, Makabali G, et al. Consumable oxygen: Availability of oxygen in relation to oxyhemoglobin dissociation. Crit Care Med 1973; 1: 17-21
23. Rao TLK, Montoya A. Cardiovascular, electrocardiographic and respiratory changes following acute anemia with volume replacement in patients with coronary artery disease. Anesth Dev 1985; 12: 49-54
24. Parksloe MRJ, Wuld R, Fox M, et al. Silent myocardial ischemia in a patient with anaemia before operation. Br J Anaesth 1990; 64: 634-7
25. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993; 21: 860-6
26. Hogue CW, Goodnough LT, Monk TG. Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy. Transfusion 1998; 38: 924-31
27. Spiess BD, Ley C, Body SC, et al: Hematocrit value on intensive care unit entry influences the frequency of Q-wave myocardial infarction after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1998; 116: 460-7
28. Bracey AW, Radovancevic R, Riggs SA, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999; 39: 1070-7
29. Goodnough LT, Vizmeg K, Riddell J, et al. Discharge hematocrit as clinical indicator for blood transfusion audit in surgery patients. Transfus Med 1994; 4: 35-44
30. Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm on physician transfusion behavior in cardiac surgery. Transfusion 1994; 34: 290-6
31. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site coagulation monitoring in cardiac surgical patients. J Thorac Cardiovasc Surg 1994; 107: 271-9
32. Reinersten JL. Algorithms, Guidelines, and Protocols: Can they really improve what we do? Transfusion 1994; 34: 281-2
33. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001; 94: 773-81
34. Sehgal LR, Zebala LP, Takagi I, et al. Evaluation of oxygen extraction ratio as a physiologic transfusion trigger in coronary artery bypass graft surgery patients. Transfusion 2001; 41; 591-5
35. NHLBI Expert Panel. Transfusion alert: Use of autologous blood. Transfusion 1995; 35: 703-11
36. National Heart, Lung, and Blood Institute Autologous Transfusion Symposium Working Group. Autologous transfusion: Current trends and research issues. Transfusion 1995; 35: 525-31
37. Consensus Conference on Autologous Transfusion. Final consensus statement. Transfusion 1996; 36: 667
38. British Committee for Standards in Hematology, blood transfusion task force: Guidelines for autologous transfusion. Transfus Med 1993; 307-16
39. Goodnough LT, Price TH, Rudnick S. Iron restricted erythropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone marrow. J Lab Clin Med 1991; 118: 289-96
40. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: The relevance of storage iron. Vox Sang 1998; 75: 128-33
41. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-33
42. Mann M, Sacks HJ, Goldfinger D. Safety of autologous blood donation prior to elective surgery for a variety of potentially high risk patients. Transfusion 1983; 23: 229-32
43. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995; 35: 734-7
44. Birkmeyer JD, Aubuchon JP, Littenberg B, et al. The costs and benefits of preoperative autologous blood donation in elective coronary bypass surgery. Ann Thorac Surg 1994; 57: 161-9
45. Kruskall MS, Yomtovian R, Dzik WH, et al. On improving the cost-effectiveness of autologous blood transfusion practices. Transfusion 1994; 34: 259-64
46. Spiess BD, Sassetti R, McCary RJ, et al. Autologous blood donation. Hemodynamics in a high-risk patient population. Transfusion 1992; 32: 17-22
47. Owings DV, Kruskall MS, Thurer RL, et al. Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use. JAMA 1989; 262: 1963-7
48. Dzik WH, Fleisher AG, Ciavarella D, et al. Safety and efficacy of autologous blood donation before elective aortic valve operation. Ann Thorac Surg 1992; 54: 1177-80
49. National Blood Resource Education Program Expert Panel. The use of autologous blood. JAMA 1990; 263: 414-7
50. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30: 583-90
51. Johnson RG, Thurer RL, Kruskall MS, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg 1992; 104: 307-14
52. Welch GH, Meehan K, Goodnough LT. Prudent strategies for elective red cell transfusion. Ann Intern Med 1992; 116: 393-403
53. Petry AF, Jost T, Sievers H. Reduction of homologous blood requirements by blood pooling at the onset of cardiopulmonary bypass. J Thor Cardiovasc Surg 1994; 107: 1210-4
54. Mohr R, Martinowitz U, Lavee J, et al. The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thor Cardiovasc Surg 1988; 96: 530-4
55. Lavee J, Martinowitz U, Mohr R, et al. The effect of transfusion of fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg 1989; 97: 204-12
56. Sowade O, Warneke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with recombinant human erythropoietin in patients undergoing open heart surgery. Blood 1997; 89: 411-8
57. Robblee JA. Blood harvested before cardiopulmonary bypass decreased postoperative blood loss: Pro. J Cardiothor Anesth 1990; 4: 519-22
58. Starr NJ. Con: Blood should not be harvested immediately before cardiopulmonary bypass and infused after protamine reversal to decrease blood loss following cardiopulmonary bypass. J Cardiothorac Anesth 1990; 4: 522-5
59. Ray JM, Flynn JC, Bierman AH. Erythrocyte survival following intraoperative autotransfusion in spinal surgery: An in vivo comparative study and 5-year update. Spine 1986; 11: 879-82
60. Horst HM, Dlugos S, Fath JJ, et al: Coagulopathy and intraoperative blood salvage. J Trauma 1992; 32: 5: 646-53
61. Despotis GJ, Filos KS, Zoys TN, et al: Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13-21
62. Boldt J, Zickmann B, Czeke A, et al. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology 1991; 75: 426-32
63. Linden JV, Tourault MA, Scribner CL. Decrease in frequency of transfusion fatalities. Transfusion 1997; 37: 243-4
64. Bell K, Stott K, Sinclair CJ, et al. A controlled trial of intra-operative autologous transfusion in cardiothoracic surgery measuring effect on transfusion requirements and clinical outcome. Transfus Med 1992; 2: 295-300
65. Goodnough LT, Monk TG, Sicard G, et al. Intraoperative salvage in patients undergoing elective abdominal aortic aneurysm repair. J Vasc Surg 1996; 24: 213-8
66. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: Cost and utilization issues. Am J Med Qual 1994; 9: 172-83
67. Elliott MJ. Ultrafiltration and modified ultrafiltration in pediatric open heart operations. Ann Thorac Surg 1993; 56: 1518-22
68. Naik SK, Knight A, Elliott M. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 1991; 84: 1181-9
69. Andreasson S, Gothberg S, Berggren H, et al. Hemofiltration modifies complement activation after extracorporeal circulation in infants. Ann Thorac Surg 1993; 56: 1515-7
70. Millar AB, Armstrong L, van der Linden J, et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993; 56: 1499-502
71. Journois D, Pouard P, Greeley WJ, et al. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components. Anesthesiology 1994; 81: 1181-9
72. Schaff HY, Hauer J, Gardner TJ, et al. Routine use of autotransfusion following cardiac surgery: experience in 700 patients. Ann Thorac Surg 1979; 27: 493-9
73. Cosgrove DM, Loop FD, Lytle BW, et al. Determinants of blood utilization during myocardial revascularization. Ann Thorac Surg 1985; 40: 380-4
74. Ward HB, Smith RA, Candis KP, et al. A prospective, randomized trial of autotransfusion after routine cardiac surgery. Ann Thorac Surg 1993; 56: 137-41
75. Thurer RL, Lytle BW, Cosgrove DM, et al. Autotransfusion following cardiac operations: a randomized, prospective study. Ann Thorac Surg 1979; 27: 500-6
76. Roberts SP, Early GL, Brown B, et al. Autotransfusion of unwashed mediastinal shed blood fails to decrease banked blood requirements in patients undergoing aorta coronary bypass surgery. Am J Surg 1991; 162: 477-80
77. Schaff HV, Hauer JM, Bell WR, et al. Autotransfusion of shed mediastinal blood after cardiac surgery. A prospective study. J Cardiovasc Thorac Surg 1978; 75: 632-41
78. Eng J, Kay PH, Murday AJ, et al. Post-operative autologous transfusion in cardiac surgery. A prospective, randomized study. Eur J Cardiothorac Surg 1990; 4: 595-600
79. Tyson GS, Sladen RN, Spainhour V, et al. Blood conservation in cardiac surgery. Ann Surg 1989; 209: 736-42
80. Goodnough LT. Blood conservation and blood transfusion practices: Flip sides of the same coin. Ann Thorac Surg 1993; 56: 3-4
81. Vamvakas EC, Pineda AA. Autologous transfusion and other approaches to reduce allogeneic blood exposure. Baillieres Clin Haematol 2000; 13: 533-47
82. Goodnough LT. The case against universal leukoreduction (and for the practice of evidence-based medicine). Transfusion 2000; 40: 1522-7
83. Weiskopf RB. Efficacy of acute normovolemic hemodilution assessed as a function of fraction of blood volume lost. Anesthesiology 2001; 94: 439-6
84. Goodnough LT, Despotis GJ, Merkel K, et al. A randomized trial of acute normovolemic hemodilution compared to preoperative autologous blood donation in total hip arthroplasty. Transfusion 2000; 40: 1054-7
85. Toy P, Feiner J, Viele MK, et al. Fatigue during acute isovolemic anemia in healthy, resting humans. Transfusion 2000; 40: 457-60
86. -1. Anesthesiology 2000; 92: 406-13
87. Joint Council of the American Red Cross, Council of Community Blood Centers, American Association of Blood Banks. Circular of information for the use of human blood components. 1994 Mar, 9
88. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933-8
89. Goodnough LT, Price TH and the EPO Study Group. A phase III trial of recombinant human erythropoietin therapy in non-anemic orthopaedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, and efficacy. Transfusion 1994; 34: 66-71
90. de Andrade JR, Frei D, Guilfoyle M. Integrated analysis of thrombotic/vascular event occurrence in epoietin alfa-treated patients undergoing major, elective orthpedic surgery. Orthopedics 1999; 1 Suppl.: S113-S116
91. D?Ambra MN, Gray RJ, Hillman R, et al. The effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64: 1686-93
92. Goodnough LT, Despotis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann Thorac Surg 1997; 64: 1579-80
93. Hutchinson AB, Fergusson D, Graham ID, et al. Utilization of technologies to reduce allogeneic blood transfusion in the United States. Transfus Med 2001; 11: 79-85
94. Marchetta M, Barosi G. Cost-effectiveness of epoietin and autologous blood donation in reducing allogeneic blood transfusions in coronary artery bypass graft surgery. Transfusion 2000; 40: 673-81
95. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Nat Acad Sci 2000; 97: 10526-31
96. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-701
97. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 Suppl. 1: 3-10
98. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001; 84 Suppl. 1: 17-23
99. Smith RE, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001; 84 Suppl. 1: 24-30
100. Sakariassen KS, Cattaneo M, v.d.Berg A, et al. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-36
101. Kanwar S, Woodman RC, Poon MC, et al. Desmopressin induces endothelial Pselectin expression and leukocyte rolling in postcapillary venules. Blood 1995; 86: 2760-6
102. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12
103. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. BMJ 1985; 291: 1377-81
104. Kobrinsky NL, Israels ED, Gerrard JM, et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; 1: 1145-48
105. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314: 1402-6
106. Hackmann T, Gascoyne RD, Naiman SC, et al. A trial of desmopressin (1- desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989; 321: 1437-43
107. Lazenby WD, Russo I, Zadeh BJ, et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990; 82: IV413-9
108. Ansell J, Klassen V, Lew R, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg 1992; 104: 117-23
109. Casas JI, Zuazu-Jausoro I, Mateo J, et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo- controlled study. J Thorac Cardiovasc Surg 1995; 110: 1107-17
110. Temeck BK, Bachenheimer LC, Katz NM, et al. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J 1994; 87: 611-5
111. de Prost D, Barbier-Boehm G, Hazebroucq J, et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992; 68: 106-10
112. Czer LS, Bateman TM, Gray RJ, et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987; 9: 1139-47
113. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: 38-46
114. Despotis GJ, Levine V, Saleem R, Spitznagel E,Joist JH,. Use of point of care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised, controlled trial. Lancet 1999; 334: 106-10
115. Baker JW, Spotnitz WD, Matthew TL, Fechner RE, Nolan SP. Mediastinal fibrin glue: hemostatic effect and tissue response in calves. Ann Thorac Surg 1989; 47: 450-2
116. Silberstein LE, Williams LJ, Hughlett MA, et al. An autologous fibrinogen-based adhesive for use in otologic surgery. Transfusion 1988; 28: 319-21
117. Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant? Transfusion 1990; 30: 741-7
118. Milde LN. An anaphylactic reaction to fibrin glue. Anesth Analg 1989; 69: 684-6
119. Wilson SM, Pell P, Donegan EA. HIV-1 transmission following the use of cryoprecipitated fibrinogen as gel/adhesive [abstract]. Transfusion 1991; 31: 51S
120. Burnouf-Radosevich M, Burnouf T, Huart JJ. Biochemical and physical properties of a solvent-detergent-treated fibrin glue. Vox Sang 1990; 58: 77-84
121. Banninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85: 528-32
122. Teoh KH, Christakis GT, Weisel RD, et al. Blood conservation with membrane oxygenators and dipyridamole. Ann Thorac Surg 1987; 44: 40-7
123. Fish KJ, Sarnquist FH, van Steennis C, et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg 1986; 91: 436-42
124. DiSesa VJ, Huval W, Lelcuk S, et al. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. Ann Thorac Surg 1984; 38: 514-9
125. Despotis GJ, Hogue CW. Pathophysiology, prevention, and treatment of bleeding after cardiac surgery: A primer for cardiologist and an update for the cardiothoracic team. Am J Cardiol 1999; 83: 15B-30B
126. Horrow JC. Desmopressin and antifibrinolytics [review]. Int Anesthesiol Clin 1990; 28: 230-6
127. Lambert CJ, Marengo-Rowe AJ, Leveson JE, et al. The treatment of postperfusion bleeding using epsilon-aminocaproic acid, cryoprecipitate, fresh-frozen plasma, and protamine sulfate. Ann Thorac Surg 1979; 28: 440-4
128. Vander Salm TJ, Ansell JE, Okike ON, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg 1988; 95: 538-40
129. Horrow JC, Hlavacek J, Strong MD, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 70-4
130. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. J Thorac Cardiovasc Surg 1995; 110: 835-42
131. Ovrum E, Am Holen E, Abdelnoor M, Oystese R, Ringdal ML. Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg 1993; 105: 78-83
132. Bidstrup BP, Harrison J, Royston D, et al. Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971-6
133. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983; 33: 479-94
134. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995; 83: 679-89
135. Marx G, Pokar h, Reuter H, et al. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5: 467-74
136. Poullis M, Manning R, Laffan M, et al. The anti-thrombotic effect of aprotinin: Actions mediated through the protease-activated receptor 1. J Thorac Cardiovasc Surg 2000; 120: 370-8
137. Sweeney JD, Blair AJ, Dupuis MP, et al. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion 1997; 37: 1173-8
138. Lemmer Jr JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-53
139. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92: 2236-44
140. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996; 62: 1659-67
141. Alderman EL, Levy JH, Rick JB, et al. Analyses of coronary graft patency after aprotinin use: results from the international multicenter aprotinin graft patency experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716-30
142. Slaughter TF, Faghih F, Greenberg CS, et al. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997; 85: 1221-6
143. Montesano RM, Gustafson PA, Palanzo DA, et al. The effect of low-dose epsilonaminocaproic acid on patients following coronary artery bypass surgery. Perfusion 1996; 11: 53-6
144. Vander Salm TJ, Kaur S, Lancey RA, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996; 112: 1098-7
145. Karski JM, Teasdale SJ, Norman PH, et al. Prevention of post-bypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth 1993; 7: 431-5
146. DelRossi AJ, Cernaianu AC, Botros S, et al. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989; 96: 27-30
147. McClure PD, Izsak J. The use of epsilo-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology 1974; 40: 604-8
148. Midell AI, Hallman GL, Bloodwell RD, et al. Epsilon-aminocaproic acid for bleeding after cardiopulmonary bypass. Ann Thorac Surg 1971; 11: 577-82
149. Trinh-Duc P, Wintrebert P, Boulfroy D, et al. Comparison of the effects of epsilon- aminocaproic acid and aprotinin on intra- and postoperative bleeding in heart surgery. Ann Chir 1992; 46: 677-83
150. de Peppo AP, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and bloodsaving techniques in cardiac surgery. Texas Heart Inst J 1995; 22: 231-6
151. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg 1996; 37: 401-7
152. Bennett-Guerrero E, Sorohan JG, Gurevich ML, et al. Cost-benefit and efficacy of aprotinin compared with epsilon- aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology 1997; 87: 1373-80
153. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low- dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1995; 9: 240-4
154. Blauhut B, Harringer W, Bettelheim P, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 1083-91
155. Speekenbrink RG, Vonk AB, Wildevuur CR, et al. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995; 59: 438-2
156. Sundt TM, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-24
157. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-8
158. Westaby S, Katsumata T. Aprotinin and vein graft occlusion-the controversy continues [editorial]. J Thor Cardiovasc Surg 1998; 116: 731-3
159. Smith PK. Aprotinin: Safe and effective only with the full-dose regimen. Ann Thorac Surg 1996; 62: 1575-7